1μg (R: reducing condition, N: non-reducing condition).
LY75/CD205 His Tag Protein, Human
LY75/CD205 His Tag Protein, Human
Price:
Regular price
$256 USD
Regular price
Sale price
$256 USD
Unit price
per
For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details
Product Details
Product Details
Product Specification
| Species | Human |
| Synonyms | LY75, CD205, DEC-205, CLEC13B, Lymphocyte antigen 75, gp200-MR6 |
| Accession | O60449-1 |
| Amino Acid Sequence | Ser28-Asp1666 with His Tag at C-Terminus |
| Expression System | HEK293 |
| Molecular Weight | 170-200kDa (Reducing) |
| Purity | ＞95% by SDS-PAGE |
| Conjugation | Unconjugated |
| Tag | His Tag |
| Physical Appearance | Lyophilized Powder |
| Storage Buffer | PBS, PH7.4, 5% trehalose |
| Reconstitution | Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation. |
| Stability & Storage |
· 12 months from date of receipt, lyophilized powder stored at -20 to -80℃. |
| Reference | Yun Z, Liu Z, Shen Y, Sun Z, Zhao H, Du X, Lv L, Zhang Y, Hou L. Genetic analysis from multiple cohorts implies causality between 2200 druggable genes, telomere length, and leukemia. Comput Biol Med. 2024 Oct;181:109064. |
Background
Lymphocyte antigen 75 (Ly75), also known as CD205, CLEC13B, GP200-MR6, and DEC-205, is a type I transmembrane protein predominantly expressed on dendritic cells and thymic epithelial cells. Ly75 functions as an endocytic receptor for antigens. MEN1309/OBT076, the first antibody drug targeting CD205, has demonstrated strong preclinical anti-tumor activity in lymphoma models.
Upon verification as a monotherapy in vivo, the antibody-drug conjugate (ADC) has been found to have a synergistic effect when combined with the BCL2 inhibitor Venetoclax and the anti-CD20 monoclonal antibody rituximab.
Picture
Picture
SDS-PAGE
